This is why Novartis paid Trump’s lawyer Michael Cohen $1.2 million
Hiring the president’s personal attorney matches a history of aggressively courting government officials by a corporation with much to lose in the debate over high drug prices.
Could failing proton centers be a sign of a healthcare bubble?
Health systems rushed enthusiastically into expensive medical technologies such as proton beam centers. But now that employers, insurers and government seem determined to curb growth in healthcare spending and to combat overcharges and wasteful procedures, such bets are less of a sure thing.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A look at how one pharma company responded to the pressure on drug prices: Ramping up political activity
The pharma industry as a whole has cranked up political contributions and lobbying. Meanwhile, despite much talk about change, Congress and the Trump administration have done little to control drug prices or threaten drug-company profits.
Battleground on drug price legislation shifts to states and so does lobbying by PhRMA
With federal officials seemingly unwilling or unable to come up with legislation to control skyrocketing drug prices, that task is increasingly moving to the states. But so is pharma muscle and money opposing the measures.
Facing showdown on high drug prices, industry group PhRMA revenue surges to highest level in 7 years
Pharmaceutical Research and Manufacturers of America’s state and federal lobbying spending rose by more than two-thirds from the previous year, to $57 million.
Turmoil with ACA individual insurance marketplace abounds under Trump administration
Many of plans that people relied on for 2017 are being canceled, the result of insurers exiting the marketplaces or redesigning coverage to try to keep premiums down.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Outcome far from certain in legal battle over cost-sharing ACA payments
A legal fight over the federal government's practice of paying cost-sharing reduction subsidies to insurers as part of the Affordable Care Act inched ahead with a small victory for insurers this week.
Back where we started? Senate health bill adds uncertainty for people with chronic conditions
Insurers were struggling last week to grasp the implications of the legislation, studded with ambiguous language. One big takeaway: The Senate’s version of health care would undermine historical assumptions and drastically shift risk in the individual market.
Loopholes in Senate healthcare bill risk eroding coverage for pre-existing conditions
Built into the bill are loopholes for states to bypass those protections and erode coverage for preexisting conditions.
As House health bill vote nears, what would be consequences of dumping essential benefits?
Experts on both sides of the debate say it will likely also induce insurers to offer much skimpier plans, potentially excluding the gravely ill.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Australian biotech company offered sweetheart investment deal to Tom Price
Price told HHS ethics officials Thursday that if appointed to be HHS secretary, he will divest himself of the Australian stock as well as stock in about 40 other companies that could pose conflicts.
Insurance companies need to fix their provider directories
Flawed directories are “a real barrier to accessing the care and accessing the insurance consumers have purchased.”
ACA replacement may not be all that radical
Topping the list of ACA provisions likely to survive under Trump is the requirement that employers cover workers’ children up to the age of 26, analysts said.
Researchers visualize dubious benefits of many ‘routine’ screening tests
Under the growing philosophy of “shared decision-making,” they just want patients to have a good conversation about what procedures can and can’t do. Then patients decide.
Baltimore’s population health ‘moonshot’ aims at racial disparities
Baltimore officials presented a 10-year plan Tuesday that sharply highlights the poor health status of African-Americans and aims to bring black rates of lead poisoning, heart disease, obesity, smoking and overdoses more in line with those of whites.